Do Generic EGFR-TKIs Perform as Well as Innovators? Real-World Evidence from Gefitinib-Treated EGFR-Mutated NSCLC in Indonesia
- DOI
- 10.31557/apjcp.2026.27.8.2969
- Published
- 2026-08-01
- Container
- Asian Pacific Journal of Cancer Prevention
- Publisher
- EpiSmart Science Vector Ltd
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.31557/apjcp.2026.27.8.2969,
title = {Do Generic EGFR-TKIs Perform as Well as Innovators? Real-World Evidence from Gefitinib-Treated EGFR-Mutated NSCLC in Indonesia},
author = {Fitri Nurhayati and Rizka Andalucia and Jarir Ath Thobari and Elisna Syahruddin and Yusi Anggriani},
year = {2026},
journal = {Asian Pacific Journal of Cancer Prevention},
doi = {10.31557/apjcp.2026.27.8.2969},
url = {https://doi.org/10.31557/apjcp.2026.27.8.2969}
}RIS
TY - JOUR TI - Do Generic EGFR-TKIs Perform as Well as Innovators? Real-World Evidence from Gefitinib-Treated EGFR-Mutated NSCLC in Indonesia AU - Fitri Nurhayati AU - Rizka Andalucia AU - Jarir Ath Thobari AU - Elisna Syahruddin AU - Yusi Anggriani PY - 2026 JO - Asian Pacific Journal of Cancer Prevention DO - 10.31557/apjcp.2026.27.8.2969 UR - https://doi.org/10.31557/apjcp.2026.27.8.2969 ER -
APA
Nurhayati, F., Andalucia, R., Thobari, J. A., Syahruddin, E., & Anggriani, Y. (2026). Do Generic EGFR-TKIs Perform as Well as Innovators? Real-World Evidence from Gefitinib-Treated EGFR-Mutated NSCLC in Indonesia. Asian Pacific Journal of Cancer Prevention. https://doi.org/10.31557/apjcp.2026.27.8.2969
Source records
- crossref · retrieved 2026-09-25T20:49:15.623Z